[Effectiveness of darbepoietin alfa in anemic patients with chronic kidney disease (CKD) in predialysis period].
Patients with chronic kidney disease (CKD) often suffer from anemia due to erythropoietin deficiency. Anemia treatment with erythropoietin in patients with chronic kidney disease can effectively maintain hemoglobin target level > 11g/dl. In this study we presented the results of anemia treatment with darbepoietin alfa in 18 patients with chronic kidney disease (3-5 stage of CKD) in predialysis period. After 10 weeks of darbepoietin alfa administration at the dose 10 microg/week, hemoglobin serum level had increased over 11 g/dl in 15 patients. In the 3 patients serum hemoglobin level during the darbepoietin alfa treatment did not increased. Between 15 patients, in 4 after 10 weeks of darbepoietin alfa treatment at the dose 10 microg/week and in 7 after 15 weeks of the treatment at the dose 15 microg/2 weeks hemoglobin serum level had increased over 13 g/dl. After 2 months with out darbepoietin alfa treatment hemoglobin serum level had decreased but still maintain the target level 11 g/dl. darbepoietin alfa was well tolerated. The results of this study demonstrate that darbepoietin alfa administered s.c. once weekly or once other week at a small doses is effective in renal anemia treatment and comfortable for a patients.